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Introduction {#sec1}
============

The liver is a central organ for metabolism, and the parenchymal cells, or hepatocytes, play key roles for homeostasis by expressing numerous metabolic and synthetic enzymes. As they express a number of cytochrome P450 oxidases (CYP450s) responsible for the oxidative biotransformation of many endogenous compounds as well as drugs, primary cultures of hepatocytes have been used for drug discovery and toxicology. However, primary hepatocytes exhibit low metabolic activity in vitro, and the supply of human hepatocytes is also limited and variable. To overcome these challenges, human embryonic stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs) have been considered as an alternative cell source for production of human hepatocytes. To date, there are many studies reporting hepatic differentiation of hiPSCs/hESCs ([@bib5], [@bib7], [@bib11]). However, in most cases, differentiation of hepatocytes from hiPSCs is accomplished by a time-consuming culture protocol with multiple differentiation steps using expensive cytokines. Also, hepatocytes derived from hiPSCs possess a limited capacity for proliferation and functional maturation. Thus, it is beneficial to develop a simplified culture system for large-scale production of mature hepatocytes from hiPSCs. As liver progenitor cells (LPCs) such as hepatoblasts proliferate extensively in vitro, it would be useful if such cells could be derived from hiPSCs.

The development of the mouse liver begins with early endoderm development. The cells of the ventral foregut endoderm are induced to the hepatoblast stage by fibroblast growth factor (FGF) and bone morphogenetic protein (BMP) signaling from the heart and septum transversum mesenchyme (STM). Following induction, hepatoblasts proliferate and migrate into the STM to form the liver bud with non-parenchymal cells, such as endothelial progenitor cells and hepatic mesenchymal cells ([@bib19]). Importantly, hepatoblasts isolated from fetal liver can be cultured long-term while maintaining the potential to differentiate into both hepatocytes and cholangiocytes, two types of liver epithelial cell ([@bib9], [@bib16]). LPCs can also be isolated from normal as well as injured adult livers and maintained in culture for long term, although their role in vivo remains elusive ([@bib4]).

It has been reported that LPC-like cells were established from hESCs/hiPSCs ([@bib12], [@bib18], [@bib20]), and these cells were shown to proliferate and differentiate into hepatocyte-like cells or cholangiocyte-like cells. These LPCs were either isolated by cell sorting using a combination of specific cell surface markers or generated by adenovirus-mediated gene transfer to promote hepatic lineage differentiation. To develop an efficient culture system for large-scale production of mature functional hepatocytes, our aim was to identify a specific cell surface marker for isolating hiPSC-derived LPCs. In this study, we identified carboxypeptidase M (CPM) as a cell surface marker for hepatoblasts. CPM was also upregulated in hiPSC-derived cells during hepatic differentiation, and the sorted CPM^+^ cells exhibited features typical of hepatoblasts. Moreover, we developed a highly efficient and reliable culture system for hiPSC-derived LPCs capable of proliferating and differentiating into both hepatocytes and cholangiocytes in vitro.

Results {#sec2}
=======

Identification of CPM as a Hepatoblast Marker {#sec2.1}
---------------------------------------------

In order to isolate LPCs from hiPSCs effectively, we searched for cell surface molecules expressed in hepatoblasts. Although CXCR4 is known to be expressed in hepatoblasts, it is also detected in endodermal progenitors, thus implying that additional markers would be required to isolate LPCs. DLK1 is an excellent marker for hepatoblasts and has been extensively used to isolate hepatoblasts. However, although immunocytochemical staining using an anti-DLK1 antibody revealed that DLK1-expressing cells were present in hiPSC-derived cells at the immature hepatocyte stage ([Figure S1](#mmc1){ref-type="supplementary-material"}A), flow cytometric (FCM) analysis showed no expression of DLK1 on the cell surface ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We therefore searched for other hepatoblast cell surface molecules. Among 627 monoclonal antibodies established against mouse fetal liver cells ([@bib10]), we previously found that 40-1 antibody binds to an unidentified cell surface protein expressed on mouse hepatoblasts ([@bib15]). By employing the expression cloning procedure, we identified CPM as the specific antigen for the 40-1 antibody ([Figure 1](#fig1){ref-type="fig"}A). Immunohistochemical studies showed that CPM is mainly expressed in endodermal tissues such as liver, thymus, lung, and gut in mouse fetus at E14.5 ([Figure 1](#fig1){ref-type="fig"}B), confirming the previous studies that CPM is widely expressed in endodermal tissues during mouse development ([@bib14]).

Next, we performed FCM analysis/cell sorting to confirm the expression of CPM in mouse hepatoblasts. CPM was coexpressed with a hepatoblast marker, DLK, and CPM^+^ cells isolated from E14.5 fetal liver also highly expressed LPC markers such as alpha-1-fetoprotein (*Afp*) and albumin (*Alb*) ([Figures 1](#fig1){ref-type="fig"}C and 1D). *Cpm* was highly expressed in fetal liver, but its expression was dramatically decreased after birth ([Figure 1](#fig1){ref-type="fig"}E) and was undetectable in mature hepatocytes and cholangiocytes ([Figure 1](#fig1){ref-type="fig"}F). Collectively, these data demonstrated that CPM is strongly expressed in hepatoblasts and fetal LPCs ([Figure 1](#fig1){ref-type="fig"}G) and also suggested that CPM may be a useful marker for enrichment of LPCs from differentiating hiPSCs.

CPM Expression during Hepatic Differentiation from Human iPSCs {#sec2.2}
--------------------------------------------------------------

To evaluate whether CPM could be used as a marker for enrichment of LPCs from hiPSCs, we first analyzed the expression levels of *CPM* in human fetal liver. *CPM* was highly expressed in human fetal liver from 6 to 12 weeks of gestation, but was expressed at very low levels in adult liver and HepG2 cells, a human hepatocellular carcinoma cell line ([Figure 2](#fig2){ref-type="fig"}A). We then examined the CPM expression profile during hepatic differentiation from hiPSCs by qRT-PCR and FCM analysis. As described in the previously reported protocol, we induced hepatic differentiation in two hiPSC lines (454E2 and 409B2). hiPSCs showed morphological changes after induction toward the hepatic lineage ([Figure S2](#mmc1){ref-type="supplementary-material"}A), with rapid downregulation of OCT4 and sequential induction of GATA4, SOX17, FOXA2, and HNF4α ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). In this culture system, the expression level of *CPM* was undetectable in undifferentiated hiPSCs, but upregulated together with hepatic progenitor markers such as FOXA2 and HNF4α during differentiation ([Figures 2](#fig2){ref-type="fig"}B, [S2](#mmc1){ref-type="supplementary-material"}B, and S2C). FCM analysis revealed that 20% of specified hepatic cells were CPM^+^, with this population increasing to ∼40% after differentiation to immature hepatocytes. CPM expression decreased along with subsequent hepatic maturation ([Figure 2](#fig2){ref-type="fig"}C). Collectively, these data showed that CPM is a specific cell surface marker for human iPSC-derived LPCs.

Enrichment of hiPSC-Derived LPCs Based on the Expression of CPM {#sec2.3}
---------------------------------------------------------------

To further characterize the CPM^+^ cells derived from hiPSCs, we used a magnetic cell sorter to isolate the cells of interest and established a culture system to expand them. The purity of enriched CPM^+^ cells was over 97% after isolation by single step sorting using a magnetic cell sorter ([Figure 2](#fig2){ref-type="fig"}D). CPM^+^ cells formed compact colonies on MEF feeder cells and exhibited epithelial-like morphology, whereas no such colonies were formed from CPM^−^ cells ([Figure 2](#fig2){ref-type="fig"}E). CPM^+^ cells exhibited a high proliferative capacity and grew to confluence by day 7 after seeding ([Figure 2](#fig2){ref-type="fig"}F). These cells continued to expand after several passages in vitro ([Figure 2](#fig2){ref-type="fig"}G). Immunocytochemistry demonstrated that all CPM^+^ cells strongly expressed AFP and HNF4α, a key transcription factor for LPCs ([Figure 2](#fig2){ref-type="fig"}E). These cells could also be cultured even after several passages ([Figure S2](#mmc1){ref-type="supplementary-material"}D) or cryopreservation ([Figure S2](#mmc1){ref-type="supplementary-material"}E). In addition to *AFP* and *HNF4*α, hepatoblast markers *HNF1*α, *PROX1*, *TBX3*, *CD13*, *EpCAM*, and *HHEX* were significantly enriched in CPM^+^ cells compared with CPM^−^ cells ([Figure 2](#fig2){ref-type="fig"}H). In contrast, *CD133*, a cholangiocyte marker, was significantly expressed in CPM^−^ cells. All these data strongly suggested that CPM is a useful cell surface marker to enrich for LPCs in hiPSC-derived immature hepatic cells. Similar results were obtained from a different hiPSC line (409B2) ([Figure S2](#mmc1){ref-type="supplementary-material"}F), indicating that the efficiency of our method for generating CPM^+^ LPCs is not cell line-dependent.

Differentiation of Hepatocytes and Cholangiocytes from CPM^+^ LPCs {#sec2.4}
------------------------------------------------------------------

It is well established that LPCs differentiate into both hepatocytes and cholangiocytes. Therefore, we evaluated the differentiation potential of CPM^+^ LPCs. After expansion of the CPM^+^ population by serial passages on MEF feeder cells, these cells were then differentiated into hepatocytes by addition of Oncostatin M ([Figure 3](#fig3){ref-type="fig"}A). As shown in [Figure 3](#fig3){ref-type="fig"}B, the hepatocytes from CPM^+^ LPCs showed typical human primary hepatocyte morphology, with binuclear cells delineated distinctly by bright borders. In addition, these cells exhibited high level expression of ALB, accumulation of glycogen and uptake of Dil-Ac-LDL ([Figures 3](#fig3){ref-type="fig"}C--3E), indicative of mature hepatocytes. FCM analysis showed that almost all differentiated cells expressed ALB ([Figure S3](#mmc1){ref-type="supplementary-material"}A). The levels of hepatic gene expression such as *CYP3A4*, *CYP2C19*, *CYP2C18*, *CYP2D6*, *CYP1A2*, and *CYP2C8* in hepatocyte-like cells derived from CPM^+^ LPCs were much higher than those derived from hiPSCs by the conventional differentiation protocol ([Figure 3](#fig3){ref-type="fig"}F). Furthermore, hepatocytes derived from CPM^+^ LPCs secreted high amounts of ALB and urea into the culture medium ([Figure 3](#fig3){ref-type="fig"}G) and exhibited high CYP3A4 activity ([Figure 3](#fig3){ref-type="fig"}H). In addition, CYP3A4 activity was significantly induced in response to rifampicin treatment, which is a well-known CYP3A4 inducer ([Figure 3](#fig3){ref-type="fig"}H). Collectively, hepatocytes derived from CPM^+^ cells exhibited higher metabolic activity compared to those derived from hiPSCs using a conventional protocol.

Furthermore, CPM^+^ LPCs were converted to cholangiocytes, which formed cysts with the luminal structure in vitro after culturing in a gel consisting of collagen and Matrigel ([Figures 4](#fig4){ref-type="fig"}A, 4B, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). The expression of *AFP* was dramatically decreased after differentiation ([Figure 4](#fig4){ref-type="fig"}C). Moreover, immunohistochemistry showed that F-actin, PKC, and AQP1 localized to the apical membrane, whereas CD49f was detected in the basolateral membrane in cystic cells ([Figures 4](#fig4){ref-type="fig"}D--4F), thus showing the proper apico-basal structure. In this culture system, cells derived from CPM^+^ LPCs highly expressed cholangiocyte marker genes, such as *CK7*, *CFTR*, *AQP1*, *TGR5*, *SOX9*, and *HNF6*, compared with iPSC-derived cholangiocytes (without CPM purification process) ([Figure 4](#fig4){ref-type="fig"}G). These results indicate that CPM^+^ LPCs can differentiate into both hepatocyte-like cells and cholangiocyte-like cells.

Discussion {#sec3}
==========

Generation of mature hepatocytes and cholangiocytes from iPS/ES cells requires time-consuming multiple processes with expensive cytokines. Therefore, it would be beneficial to derive expandable precursor cells to simplify the procedure. Because LPCs are able to proliferate extensively in vitro and differentiate to both hepatocytes and cholangiocytes ([@bib9], [@bib16], [@bib17]), they are ideal cells to use in developing an efficient protocol for large-scale production of mature liver cells. In order to isolate LPCs, we first tested the expression of DLK1 and CXCR4, which are well known to be expressed in hepatoblasts. However, neither of these markers was appropriate for enriching LPCs from hiPSC-derived cells, as described above. We therefore searched for another marker and showed that CPM is a cell surface antigen expressed on hepatoblasts in mouse fetal liver between E11.5 and E17.5, although its expression is dramatically downregulated in mature hepatocytes and cholangiocytes. CPM is a member of the carboxypeptidase family, expressed on the cell surface to catalyze the release of C-terminal arginine or lysine residues of peptides and proteins ([@bib8]). While its role in hepatoblasts is currently unknown, we found that the expression of CPM was gradually upregulated along with hepatic differentiation from hiPSC-like liver development. The simple method of single step cell sorting based on CPM expression made it possible to enrich the LPC fraction after induction of hiPSCs to the immature hepatocyte stage. These CPM^+^ cells exhibited a high proliferative potential and the expanded cells could be cryopreserved. Moreover, they expressed various liver progenitor markers ([Figure 2](#fig2){ref-type="fig"}H). While most CPM^+^ cells expressed HNF4α ([Figure 2](#fig2){ref-type="fig"}E), expression of midgut/hindgut markers such as *CDX2* and *PDX1* was also detected by RT-PCR (data not shown), suggesting that CPM^+^ cells may contain non-liver progenitors. However, after induction of hepatic differentiation, almost all cells became hepatocytes as shown by their morphology and ALB expression ([Figures 3](#fig3){ref-type="fig"}B, 3C, and [S3](#mmc1){ref-type="supplementary-material"}A). If such non-hepatic progenitors were present in the CPM^+^ cells, they did not affect hepatocyte differentiation.

CPM^+^ LPCs were able to differentiate in a single step culture to either hepatocyte-like cells or cholangiocyte-like cells depending on the culture condition. Furthermore, hepatocytes derived from CPM^+^ cells exhibited a significantly higher level of metabolic activity compared to the hiPSC-derived hepatocytes using a conventional differentiation protocol. Importantly, these hepatocyte-like cells remain phenotypically stable for more than 2 weeks ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Thus, CPM^+^ LPCs derived from hiPSCs will be useful for developing a reliable long-term hepatocyte culture system, and this simplified purification method will contribute to basic and clinical research related to liver diseases. Although CPM^+^ hepatocytes highly expressed mature hepatic genes involved in glucogenesis (*G6PC*, *PCK1*) and the urea cycling (*CPS1*), they exhibited variable levels of CYP expression compared with cultured primary human hepatocytes ([Figure S3](#mmc1){ref-type="supplementary-material"}C). It is well known that the capacity to metabolize drugs is variable due to genetic polymorphisms in CYPs ([@bib3]). Hepatocyte-like cells differentiated from iPSCs are highly variable due to retention of donor-specific metabolic capacity ([@bib13]), suggesting that the expression of CYPs in CPM^+^ Hepatocytes may be affected by a donor's genetic background.

Because freshly isolated hepatocytes rapidly lose their functions, it is a major challenge to generate fully functional hepatocytes from pluripotent stem cells. While hepatocytes derived from CPM^+^ LPCs expressed high levels of metabolic activity, the levels of some proteins are not as high as primary human hepatocytes and there is still room for improvement. During embryogenesis, hepatoblasts differentiate into mature hepatocytes through interactions with non-parenchymal cells. As non-parenchymal cells are in direct contact with hepatoblasts and also produce various cytokines to induce hepatic maturation, co-culture of CPM^+^ hepatocytes with non-parenchymal cells may be an effective way to generate more mature hepatocytes from hiPSCs, and we are currently investigating this possibility.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Two hiPSC lines (454E2 and 409B2) were provided by RIKEN Cell Bank ([@bib6]). These cells were maintained on mitomycin C-treated (Wako Pure Chemical Industries) mouse embryonic fibroblast (MEF) feeder cells, and hepatic differentiation of hiPSCs was induced using the four-step protocol previously reported, with minor modifications ([@bib7]).

Isolation and Expansion of LPCs Derived from hiPSCs {#sec4.2}
---------------------------------------------------

After induction of hiPSCs to the immature hepatocyte stage, cells were sorted using a MoFlo XDP cell sorter (Beckman Coulter) or autoMACS Pro Separator (Miltenyi Biotech) into CPM^+^ and CPM^−^ populations. To expand hiPSC-derived CPM^+^ cells, we modified the published method ([@bib1], [@bib2], [@bib18]) as follows: sorted cells were cultured on mitomycin c-treated MEF feeder cells (2.0 × 10^4^ cells/cm^2^) in DMEM-F12 (Sigma-Aldrich) supplemented with 10% FBS (JRH Biosciences), penicillin-streptomycin-glutamine, ITS, N-2 supplement, MEM non-essential amino acids solution, L-glutamine (Life Technologies), ascorbic acid (1 mM), nicotinamide (10 mM), N-acetylcysteine (0.2 mM) (Sigma-Aldrich), dexamethasone (1 × 10^−7^ M), HGF (20 ng/ml), EGF (10 ng/ml) (PeproTech), Y-27632 (5 μM) (Wako), and A83-01 (2.5 μM) (Tocris).

Differentiation of Hepatocytes and Cholangiocytes from CPM^+^ LPCs {#sec4.3}
------------------------------------------------------------------

To induce hepatic maturation of CPM^+^ LPCs, confluent cells were incubated in Hepatocyte Basal Medium (Lonza) supplemented with HCM SingleQuots (excluding EGF) and Oncostatin M (20 ng/ml) (PeproTech) for 5--10 days as described previously ([@bib7]). Induction of cholangiocyte differentiation was performed using the three-dimensional gel culture method previously reported ([@bib17], [@bib18]) with minor modifications. After expansion of CPM^+^ LPCs, the resulting cells were collected and re-suspended in a gel composed of 2:3 mixture of growth factor reduced Matrigel (Corning) and collagen type I (Nitta Gelatin) at a density of 1 × 10^5^ cells/50 μl. Cell suspensions were then added to a 24-well plate (Corning) and incubated for 2 hr at 37°C until solidification. The cells were then cultured in the presence of R-spondin-1 (40 ng/ml) and WNT-3a (40 ng/ml) (PeproTech) for 7 days.

Additional details of experimental procedures are available in the [Supplemental Information](#app2){ref-type="sec"}.
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![CPM Expression on Mouse Hepatoblasts\
(A) FCM analysis of Ba/F3 cells (control) (left) and Ba/F3 cells expressing CPM (right). GFP-positive CPM expressing cells were identified by using the 40-1 antibody.\
(B) Localization of CPM (brown) in E14.5 fetal mouse sagittal section.\
(C) FCM analysis of mouse fetal liver cells at E14.5 using antibodies against CPM and DLK1.\
(D) Relative *Afp* and *Alb* expression in the CPM/DLK1^neg^ (−), CPM/DLK1^low^ (+) and CPM/DLK1^high^ (++) fractions as indicated in (C). n = 1 in each group (each experiment contains two technical replicates).\
(E) RT-PCR analysis shows the expression of *Cpm* during mouse liver development (E11.5, E14.5, E17.5, Neonate, 4 weeks, 8 weeks). The product sizes of *Cpm* and *Gapdh* are 430 bp and 600 bp, respectively. Amplification of *Gapdh* was used as an internal control.\
(F) Relative *Cpm* expression in liver progenitor cells (LPC), Hep (mature hepatocytes), and Chol (mature cholangiocytes). The results are shown as the mean ± SEM of four independent experiments. (each experiment contains two technical replicates) ^∗∗∗^p \< 0.001.\
(G) Correlation between the expression of CPM and the hepatic maturation during liver development.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Enrichment of the hiPSC-Derived LPCs Based on the Expression of CPM\
(A) Relative *CPM* expression in HepG2 cells and liver tissues (adult liver, gestational ages: 6 weeks, 8 weeks, 12 weeks). n = 1 in each group (each experiment contains two technical replicates).\
(B and C) CPM mRNA and protein expression were analyzed by qRT-PCR (B) and FCM (C). iPSCs, iPS cells; DE, definitive endoderm; SH, specified hepatic; IH, immature hepatocytes; MH, mature hepatocytes. For (B), error bar represents the mean ± SEM of three independent experiments. ^∗^p \< 0.05 between iPSCs and IH, ^∗∗^p \< 0.01 between iPSCs and MH. See also [Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C.\
(D) FCM analysis of CPM expression was performed in pre- and post-sorted cells.\
(E) Morphology of the CPM^+^ cells (left upper) and CPM^−^ cells (left lower) on MEF feeder cells. Cells were cultured for 4 days. Immunohistochemical staining for AFP (green) and HNF4α (red) in CPM^+^ cells (right upper) and CPM^−^ cells (right lower). Nuclei were visualized by Hoechst 33342 staining (blue). Scale bar, 100 μm.\
(F) Growth curve of CPM^+^ cells. Each value was determined in triplicate. Error bar represents the mean ± SEM of three independent experiments.\
(G) Relative cell number after several passages. Error bar represents the mean ± SEM of four independent experiments.\
(H) Expression of hepatoblast markers in CPM^+^ cells compared with CPM^−^ cells. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. The results are shown as the mean ± SEM of eight independent experiments. (each experiment contains two technical replicates).\
See also [Tables S1](#mmc1){ref-type="supplementary-material"}and [S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Differentiation of Hepatocytes from hiPSC-Derived CPM^+^ LPCs\
(A) Schematic image of hepatocyte-like cell differentiation from CPM^+^ LPCs.\
(B--D) The morphology of CPM^+^ LPCs (upper) and CPM^+^ hepatocyte-like cells (lower) was investigated by microcopy. (B) Phase contrast images. CPM^+^ LPCs exhibit light cytoplasm and indistinct cell borders. CPM^+^ hepatocyte-like cells exhibit cobblestone-like morphology with binucleation. (C) Immunohistochemistry for AFP (red), ALB (green) and HNF4α (gray). Nuclei were counterstained with Hoechst 33342 (blue). (D) PAS staining showed accumulation of glycogen. Scale bars, 100 μm.\
(E) Uptake of DilAcLDL (red) in CPM^+^ hepatocyte-like cells. Scale bar, 100 μm.\
(F) qRT-PCR analysis of various CYP450s mRNA levels. The results are shown as the mean ± SEM of six independent experiments. (each experiment contains two technical replicates). iPSC-Heps was used as a control. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.\
(G) Secretion of ALB and urea. The results are shown as the mean ± SEM of seven independent experiments. iPSC-Heps was used as a control. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.\
(H) Relative CYP3A4 activity. The results are shown as the mean ± SEM of at least three independent experiments. Treatment with 10 μM of rifampicin (Rif) for 72 hr. iPSC-Heps was used as a control. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Differentiation of Cholangiocytes from hiPSC-Derived CPM^+^ LPCs\
(A) Schematic image of cholangiocyte-like cells differentiation from CPM^+^ LPCs.\
(B) Phase contrast image. CPM^+^ LPCs form cysts in collagen/Matrigel after 7 days of culture. See also [Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B.\
(C) Expression of *AFP* in CPM^+^ LPCs and CPM^+^ cholangiocytes. The results are shown as the mean ± SEM of four independent experiments (each experiment contains two technical replicates). ^∗∗^p \< 0.01.\
(D--F) Immunofluorescence staining for cholangiocyte markers in CPM^+^ cholangiocyte-like cells. Localization of (D) CK7 (red), F-actin (green), (E) CD49f (red), PKC (green), (F) β-catenin (red), AQP1 (green). Nuclei were visualized by Hoechst 33342 staining (blue). Scale bars, 100 μm.\
(G) Gene expression profile of CPM^+^ cholangiocyte-like cells compared with iPSC cholangiocyte-like cells. The results are shown as the mean ± SEM of four independent experiments (each experiment contains two technical replicates). ND, not detected. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.\
See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}
